Literature DB >> 28052278

Diagnosis and Treatment Strategy of Achalasia Subtypes and Esophagogastric Junction Outflow Obstruction Based on High-Resolution Manometry.

Eikichi Ihara1, Kazumasa Muta, Keita Fukaura, Kazuhiko Nakamura.   

Abstract

BACKGROUND: Based on Chicago Classification version 3.0, the disorders of esophagogastric junction outflow obstruction (EGJOO) include achalasia (types I, II and III) and EGJOO. Although no curative treatments are currently available for the treatment of the disorders of EGJOO, medical treatments, endoscopic pneumatic dilation (PD), laparoscopic Heller myotomy (LHM), and per-oral endoscopic myotomy (POEM) are usually the sought-after modes of treatment. Since the etiology and pathogenesis might vary depending on the types of EGJOO disorders, treatment strategies should be considered based on those subtypes.
SUMMARY: Based on the accumulated evidences, the treatment strategies of our institution are as follows: effects of medical treatments on achalasia are limited. Either PD or LHM/POEM can be considered a first-line in achalasia type I, according to the patient's wish. PD and POEM can be considered first-line in achalasia types II and III, respectively. Conversely, In EGJOO, medical treatments including drugs like acotiamide and/or diltiazem can be tested as a first-line, and PD and POEM will be considered second and third-line treatments, respectively. Key Messages: The classification of subtypes based on high-resolution manometry will help us consider which treatment option can be selected as a first-line treatment depending upon the subtypes of disorders of EGJOO. Acotiamide has the potential to cure patients with EGJOO.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28052278     DOI: 10.1159/000452354

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

Review 1.  Achalasia: current therapeutic options.

Authors:  Zubin Arora; Prashanthi N Thota; Madhusudhan R Sanaka
Journal:  Ther Adv Chronic Dis       Date:  2017-06-23       Impact factor: 5.091

Review 2.  Advances in Management of Esophageal Motility Disorders.

Authors:  Peter J Kahrilas; Albert J Bredenoord; Dustin A Carlson; John E Pandolfino
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-24       Impact factor: 11.382

Review 3.  Expert consensus document: Advances in the management of oesophageal motility disorders in the era of high-resolution manometry: a focus on achalasia syndromes.

Authors:  Peter J Kahrilas; Albert J Bredenoord; Mark Fox; C Prakash Gyawali; Sabine Roman; André J P M Smout; John E Pandolfino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

Review 4.  Dysphagia in the Elderly.

Authors:  Scott M Smukalla; Irina Dimitrova; Jeremy M Feintuch; Abraham Khan
Journal:  Curr Treat Options Gastroenterol       Date:  2017-09

5.  Myotomy length informed by high-resolution esophageal manometry (HREM) results in improved per-oral endoscopic myotomy (POEM) outcomes for type III achalasia.

Authors:  Erica D Kane; Vikram Budhraja; David J Desilets; John R Romanelli
Journal:  Surg Endosc       Date:  2018-07-27       Impact factor: 4.584

Review 6.  Evaluation of Esophageal Motility and Lessons from Chicago Classification version 4.0.

Authors:  Priya Sharma; Rena Yadlapati
Journal:  Curr Gastroenterol Rep       Date:  2022-01

7.  A Case of Sub-Diaphragmatic Abscess after Injection of Botulinum Toxin to Treat Achalasia.

Authors:  Constantine Fisher; Frances Puello; Samson Ferm; Moshe Rubin; H Alan Schnall
Journal:  ACG Case Rep J       Date:  2017-11-22

8.  Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients.

Authors:  Abid T Javed; Kevin Batte; Mohamed Khalaf; Mustafa Abdul-Hussein; Pooja S Elias; Donald O Castell
Journal:  BMC Gastroenterol       Date:  2019-11-11       Impact factor: 3.067

9.  Elevated Intrabolus Pressure Predicts Abnormal Timed Barium Esophagram in Esophagogastric Junction Outflow Obstruction.

Authors:  Matthew Hoscheit; Scott Gabbard
Journal:  J Neurogastroenterol Motil       Date:  2019-10-30       Impact factor: 4.924

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.